Dordrecht

• A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax P … Recruiting
  2024-517131-52-00 5 2025-11-03 Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lym
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting
  2024-516652-18-00 5 2025-10-10 Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
• An open-label study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive pro … Recruiting
  2024-520156-22-00 4 2025-10-08 Metastatic hormone-sensitive prostate cancer
• Continuing ovulation induction with letrozole versus switching to gonadotropins in women with polycystic ovary syndrome (MOVIN-II study) Recruiting
  2024-519354-36-00 6 2025-08-01 Polycystic ovary syndrome (PCOS)
• A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity Recruiting
  2023-506260-14-00 4 2025-05-13 multiple myeloma
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu … Recruiting
  2023-506460-14-00 5 2025-05-07 Chronic kidney disease (CKD) and hypertension.
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• A clinical study of zilovertamab vedotin in people with large B-cell lymphoma (MK-2140-010) Recruiting
  2024-515566-13-00 5 2025-03-19 Diffuse Large B-Cell Lymphoma (DLBCL)
• Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca … Recruiting
  2022-502352-31-00 5 2025-02-10 Colorectal Cancer (CRC)
• BuLLSEYE Recruiting
  2024-512950-13-00 11 2025-01-03 Sepsis
• Optimizing therapy with n=1-studies: negating the 'nocebo' effect in statin-intolerance Recruiting
  2023-507489-20-00 6 2024-12-10 Statin-intolerance
• Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial Recruiting
  2024-513092-40-00 6 2024-12-05 Stroke
• Ulipristal versus surgery for symptomatic uterine fibroids Recruiting
  2024-512602-26-00 6 2024-12-02 Uterine fibroids
• Iberdomide combined with low-dose cyclophosphamide and dexamethasone: ICON study Recruiting
  2023-508902-66-00 4 2024-11-28 relapsed / refractory multiple myeloma
• DAROTAXEL Recruiting
  2024-516939-28-00 4 2024-10-28 metastatic castration-resistant prostate cancer
• HOVON 170 DLBCL: ANTICIPATE: Prevention of ANThracycline-Induced Cardiac dysfunction by dexrazoxane In PATients with diffusE large B-cell ly … Recruiting
  2023-505377-32-00 5 2024-08-15 Diffuse large B-cell lymphoma (DLBCL)
• COMPARE STEMI ONE- Comparison Of reduced DAPT followed by P2Y12 inhibitor Monotherapy with Prasugrel vs stAndard Regimen in STEMI patients t … Recruiting
  2024-515883-30-00 6 2024-08-01 St-Elevated Myocardial Infartion
• PreVent-ACaLL Recruiting
  2024-511072-33-00 4 2024-06-12 Chronic Lymphocytic Leukemia
• C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL … Recruiting
  2023-507871-23-00 5 2024-05-27 Relapsed/Refractory Multiple Myeloma
• FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting
  2023-508586-33-00 5 2024-05-14 multiple myeloma
• Phase 3 study to assess the efficacy and safety of Givinostat versus hydroxyurea in Polycythemia Vera patients Recruiting
  2022-502276-23-00 5 2024-04-25 JAK2V617F-positive high-risk Polycythemia Vera
• Bomedemstat vs Best Available Therapy (BAT) for Essential Thrombocythemia Recruiting
  2023-504865-21-00 5 2024-04-15 Essential Thrombocythemia patients who have an inadequate response to
• HOVON 165 CLL: A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in pa … Recruiting
  2022-500305-40-00 9 2024-04-10 Small Lymphocytic Lymphoma
• VulVaccin study Recruiting
  2023-506792-94-00 11 2024-03-04 Vulvar High-Grade Squamous Intraepithelial Lesion (vHSIL)

Showing 25–48 of 120 trials